Skip to main content
FRMSL logo

FRMSL — Investor Relations & Filings

Ticker · 4746 ISIN · TW0004746003 TW Manufacturing
Open in API
Filings indexed 1,872 across all filing types
Latest filing 2022-11-04 Regulatory Filings
Country TW Taiwan
Listing TW 4746

About FRMSL

www.formosalab.com

Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company provides integrated services ranging from process development and custom synthesis to large-scale commercial manufacturing. Its core product portfolio includes UV-filters, Vitamin D derivatives, and polymers such as cholesterol and phosphate binders. Formosa Laboratories offers specialized expertise in Antibody-Drug Conjugates (ADCs) and injectable manufacturing, including cytotoxic and freeze-dried products. Maintaining high quality standards, its facilities are cGMP-compliant and have been successfully inspected by the US FDA, TFDA, EDQM, and PMDA. The company serves a global clientele, providing one-stop solutions for complex chemical synthesis, fermentation, and peptide production.

Recent filings

Filing Released Lang Actions
111年10月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (台耀) providing information about fund lending balances and endorsement guarantees for the current and previous month, including limits and cumulative amounts. The content is concise, numerical, and regulatory in nature, without detailed financial statements or management discussion. The document length is only 613 characters, indicating it is a short regulatory announcement rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. It fits best as a Regulatory Filing (RNS) because it is a general compliance disclosure that does not fit other specific categories.
2022-11-04 Chinese
111年10月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report from a listed company (台耀) showing monthly and cumulative net operating revenue figures for October 2022 (民國111年10月). It includes percentage changes compared to the previous year and explanatory notes about accounting standards (IFRS) and reporting practices. The document is short (773 characters) and primarily provides financial summary data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release with key highlights. It is more of a regulatory or compliance filing providing monthly revenue data. Given the short length and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement of financial data rather than a full financial report or earnings release.
2022-11-04 Chinese
111年09月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and related parties of the company 台耀化學股份有限公司. It lists shareholdings by directors, independent directors, general manager, vice general managers, and other key personnel. The document includes data such as shares held at appointment, current shares held, pledged shares, and percentages. There is no indication of financial statements, earnings data, or management discussion. The document is not a report or announcement of a meeting, dividend, or financing. It is a disclosure of insider shareholdings and pledges, which corresponds to a Director's Dealing report or insider share transactions. Given the nature of the data and the focus on insider holdings and pledges, the appropriate classification is Director's Dealing (DIRS). The document length is 4170 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report.
2022-10-13 Chinese
111年09月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, general managers, and their related parties. It shows changes in shareholdings, types of shares held, and other related insider share transaction data. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider share transactions and holdings disclosures. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed insider shareholding data, not just an announcement or summary. Therefore, the appropriate classification is DIRS.
2022-10-13 Chinese
111年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (台耀) providing information about fund lending balances and endorsement guarantees for the current and previous months, including limits and cumulative amounts. The content is brief (613 characters) and consists mainly of tabular financial data related to fund lending and guarantees, without detailed financial statements or analysis. It does not present a full financial report, earnings release, or management discussion. It appears to be a regulatory disclosure or compliance update rather than a comprehensive report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-05 Chinese
111年9月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 台耀, with data for September 2022 (民國111年09月). It includes percentage changes compared to the previous year and explanatory notes about accounting standards (IFRS) and reporting practices. The document is very short (774 characters) and contains no detailed financial statements or management discussion. It appears to be a regulatory disclosure of monthly revenue figures rather than a full financial report or earnings release. There is no indication of a conference call transcript, AGM materials, or audit information. Given the nature and length, this fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-10-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.